The aim of this study was to investigate the effect of the combined administration of intravenous immunoglobulins and steroids as a second-line therapy in 34 children with primary immune thrombocytopenia and persistent, symptomatic bleeding. Combined therapy (intravenous immunoglobulins 0.4 g/kg daily on days 1 and 2, and methylprednisolone 20 mg/kg daily on days 1-3) was administered to 12 patients with newly diagnosed ITP who did not respond to the administration of a single therapy (either intravenous immunoglobulins or steroids) and to 22 children with persistent and chronic disease who required frequent administrations (i.e. more frequently than every 30 days) of either immunoglobulins or steroids (at the same standard dosages) in order to control active bleeding. Results. Our data suggest that the combined approach described is a well-tolerated therapeutic option for children with primary immune thrombocytopenia and persistent bleeding symptoms that can be used in both emergency and/or maintenance settings.

Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms

PARODI, Emilia;RIVETTI, ELISA;GIRAUDO, Maria Teresa;RAMENGHI, Ugo
2014-01-01

Abstract

The aim of this study was to investigate the effect of the combined administration of intravenous immunoglobulins and steroids as a second-line therapy in 34 children with primary immune thrombocytopenia and persistent, symptomatic bleeding. Combined therapy (intravenous immunoglobulins 0.4 g/kg daily on days 1 and 2, and methylprednisolone 20 mg/kg daily on days 1-3) was administered to 12 patients with newly diagnosed ITP who did not respond to the administration of a single therapy (either intravenous immunoglobulins or steroids) and to 22 children with persistent and chronic disease who required frequent administrations (i.e. more frequently than every 30 days) of either immunoglobulins or steroids (at the same standard dosages) in order to control active bleeding. Results. Our data suggest that the combined approach described is a well-tolerated therapeutic option for children with primary immune thrombocytopenia and persistent bleeding symptoms that can be used in both emergency and/or maintenance settings.
2014
12
3
340
345
http://www.bloodtransfusion.it/articolo.aspx?idart=002742&idriv=96
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111815/
Children, ITP, IVIG, Primary immune thrombocytopenia, Steroids
Parodi E; Giordano P; Rivetti E; Giraudo MT; Ansaldi G; Davitto M; Mondino A; Farruggia P; Amendola G; Matarese S; Rossi F; Russo G; Ramenghi U.
File in questo prodotto:
File Dimensione Formato  
Article_bltr.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 839.06 kB
Formato Adobe PDF
839.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Article_bltr.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 839.06 kB
Formato Adobe PDF
839.06 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/151715
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact